menu
    • menu
    [{"orgOrder":0,"company":"iCamuno","sponsor":"Second Affiliated Hospital, Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ICA07","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"iCamuno","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCamuno \/ Second Affiliated Hospital, Zhejiang University","highestDevelopmentStatusID":"6","companyTruncated":"iCamuno \/ Second Affiliated Hospital, Zhejiang University"},{"orgOrder":0,"company":"iCamuno","sponsor":"I Peace","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"iCamuno","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iCamuno \/ I Peace","highestDevelopmentStatusID":"6","companyTruncated":"iCamuno \/ I Peace"},{"orgOrder":0,"company":"iCamuno","sponsor":"Second Affiliated Hospital, Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ALC01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"iCamuno","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCamuno \/ Second Affiliated Hospital, Zhejiang University","highestDevelopmentStatusID":"6","companyTruncated":"iCamuno \/ Second Affiliated Hospital, Zhejiang University"}]

    Find Clinical Drug Pipeline Developments & Deals by iCamuno

    Menu

    iCamuno

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            iCamuno

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            iCamuno

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALC01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Second Affiliated Hospital, Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease

                            Details : ALC01 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 08, 2025

                            Lead Product(s) : ALC01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Second Affiliated Hospital, Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            iCamuno

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            iCamuno

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICA07

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Second Affiliated Hospital, Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease

                            Details : ICA07 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : ICA07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Second Affiliated Hospital, Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            iCamuno

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            iCamuno

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : I Peace

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            I Peace and iCamuno Start NK Cell Therapy Trial for Ovarian Cancer

                            Details : Company is developing an iPS cell-derived natural killer (iNK) cells. These cells are being utilized in a clinical trial aimed at treating ovarian cancer through immunotherapy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 22, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : I Peace

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth